Prosecution Insights
Prosecution Insights
10 pending office actions • 9 clients • 10 examiners • 8 art units • 0 of 10 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §103 only | 2 (20%) |
| §112 only | 2 (20%) |
| Multi-statute (no §101) | 5 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILEY, DANIEL J | 1 | 71.7% | +37.4% |
| SHIAO, YIH-HORNG | 1 | 72.6% | +75.6% |
| LAU, JONATHAN S | 1 | 64.0% | -18.2% |
| DUONG, DUC T | 1 | 89.3% | +2.2% |
| KASSA, TIGABU | 1 | 36.6% | +28.4% |
| LOCKETT, KIMBERLY R | 1 | 82.6% | +10.8% |
| MERCIER, MELISSA S | 1 | 72.1% | +6.1% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 60.4% | +64.8% |
| LI, JUN | 1 | 54.5% | +56.7% |
| NGUYEN, NGHI V | 1 | 53.5% | +50.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18594889 | STEM-LIKE PLATFORM STATION | DUONG, DUC T | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294697 | REPETITION SPRING ASSEMBLY FOR AN UPRIGHT PIANO | LOCKETT, KIMBERLY R | 76d |
| 18614126 | KIT FOR PREVENTING OR TREATING FILOVIRUS AND FLAVIVIRUS DISEASES | LAU, JONATHAN S | 82d |
| 18767062 | FALL PROTECTION SYSTEM | WILEY, DANIEL J | — |
| 18699854 | METHOD FOR CROSSLINKING HYALURONIC ACID USING RESONANT ACOUSTIC MIXING | SHIAO, YIH-HORNG | — |
| 18576567 | NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18312672 | SINGLE-ATOM CATALYSTS AND METHOD OF MANUFACTURE THEREOF | LI, JUN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17757570 | USE OF GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) FOR THE TREATMENT OF ENTERIC NEUROPATHIES | NGUYEN, NGHI V | 8d |
| 18294697 | REPETITION SPRING ASSEMBLY FOR AN UPRIGHT PIANO | LOCKETT, KIMBERLY R | 76d |
| 18588829 | PUTRESCINE SLOW-RELEASE TOPICAL FORMULATIONS | KASSA, TIGABU | 84d |
| 18767062 | FALL PROTECTION SYSTEM | WILEY, DANIEL J | — |
| 18699854 | METHOD FOR CROSSLINKING HYALURONIC ACID USING RESONANT ACOUSTIC MIXING | SHIAO, YIH-HORNG | — |
| 18576567 | NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18312672 | SINGLE-ATOM CATALYSTS AND METHOD OF MANUFACTURE THEREOF | LI, JUN | — |
| Art Unit | Apps |
|---|---|
| 3678 | 1 |
| 1693 | 1 |
| 2467 | 1 |
| 1619 | 1 |
| 2837 | 1 |
| 1615 | 1 |
| 1732 | 1 |
| 1653 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18767062 | FALL PROTECTION SYSTEM | Delta Prevention Inc. | WILEY, DANIEL J | 3678 | §102§103 | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18699854 | METHOD FOR CROSSLINKING HYALURONIC ACID USING RESONANT ACOUSTIC MIXING | Studio Bioscience Inc. | SHIAO, YIH-HORNG | §102§103§112 | Non-Final OA | — | Pending | Apr 09, 2024 | |
| 18614126 | KIT FOR PREVENTING OR TREATING FILOVIRUS AND FLAVIVIRUS DISEASES | Her Majesty The Queen In Right Of Canada AS Represented By The Minister Of Health | LAU, JONATHAN S | 1693 | §103§112 | Final Rejection | 82d | Pending | Mar 22, 2024 |
| 18594889 | STEM-LIKE PLATFORM STATION | Solutions Humanitas Inc. | DUONG, DUC T | 2467 | §112 | Non-Final OA | — | Pending | Mar 04, 2024 |
| 18588829 | PUTRESCINE SLOW-RELEASE TOPICAL FORMULATIONS | Vivier Canada Inc. | KASSA, TIGABU | 1619 | §103 | Non-Final OA | 84d | Pending | Feb 27, 2024 |
| 18294697 | REPETITION SPRING ASSEMBLY FOR AN UPRIGHT PIANO | Le Jardin Des Pianos, Location De Pianos Inc. | LOCKETT, KIMBERLY R | 2837 | §103§112 | Non-Final OA | 76d | Pending | Feb 02, 2024 |
| 18423569 | PUTRESCINE TOPICAL FORMULATIONS | Vivier Canada Inc. | MERCIER, MELISSA S | 1615 | §112 | Final Rejection | — | Pending | Jan 26, 2024 |
| 18576567 | NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | Valorisation Hsj, Limited Partnership | CUNNINGCHEN, KATHLEEN MARY | §101§102§103§112 | Non-Final OA | — | Pending | Jan 04, 2024 | |
| 18312672 | SINGLE-ATOM CATALYSTS AND METHOD OF MANUFACTURE THEREOF | Institut National De La Recherche Scientifique | LI, JUN | 1732 | §102§103§112 | Non-Final OA | — | Pending | May 05, 2023 |
| 17757570 | USE OF GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) FOR THE TREATMENT OF ENTERIC NEUROPATHIES | Transfert Plus, Société En Commandite | NGUYEN, NGHI V | 1653 | §103 | Final Rejection | 8d | Pending | Jun 17, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial